1Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients present- ing without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology( ESC ). Eur Heart J, 2016,37 : 267-315.
3Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med, 2013,369 : 999-1010.
4Bellemain-Appaix A, O'Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coro- nary intervention: a systematic review and meta-analysis. JAMA, 2012,308 : 2507-2516.
5Montalescot G, Lassen JF, Harem CW, et al. Ambulance or in- catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation my- ocardial infarction: rationale and design of the randomized, dou- ble-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J,2013,165: 515-522.
6Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med, 2014,371 : 2155-2166.
7Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of tica- grelor in patients with prior myocardial infarction. N Engl J Med, 2015,372:1791-1800.
10Bermingham M, Shanahan MK, O'Connell E, et al. Aspirin use in heart failure: is low-dose therapy associated with mortality and morbidity benefits in a large community population. Circ Heart Fail, 2014,7 : 243-250.
4[1]Rosamond W,Flegal K,Friday G,et al.Heart disease and stroke stat-istics-2007 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation,2007,115:e69-e171.
5[2]Padia SH,Kemp BA,Hewell NL,et al.Conversion of renal angiotensin Ⅱ to angiotensin Ⅲ is critical for AT2 receptor-mediated natriuresis in rats.Hypertension,2008,51:460-465.
6[3]Ramírcz-Expósito MJ,Martínez-Martos JM.Hypertension,RAS,and gender:what is the role of aminopeptidases? Heart Fail Rev,2008,24[Epub ahead of print].
